PVC Benefit-Risk Assessment 3 ā Questions and Answers
Question 1: Which patient population factor most commonly shifts a benefit-risk balance from unfavorable to favorable for a high-risk drug?
- Patients with mild, self-limiting disease
- Patients with severe, life-threatening disease with no adequate alternative therapy (Correct answer)
- Pediatric patients under age 12
- Patients with well-controlled chronic conditions
Correct answer: Patients with severe, life-threatening disease with no adequate alternative therapy
For patients with serious conditions lacking alternatives, even substantial risks may be outweighed by significant clinical benefits, shifting the balance favorably.
Question 2: The EMA's Benefit-Risk Methodology Project recommended which structured framework as most suitable for regulatory benefit-risk assessment?
- BRAT
- PrOACT-URL (Correct answer)
- MCDA
- Stochastic simulation
Correct answer: PrOACT-URL
The EMA Benefit-Risk Methodology Project concluded that PrOACT-URL (Problem, Objectives, Alternatives, Consequences, Trade-offs, Uncertainty, Risk tolerance, Linked decisions) is well-suited for regulatory use.
Question 3: When assessing benefit-risk for a biosimilar, which unique consideration differs from assessment of a novel drug?
- The biosimilar must demonstrate superiority in efficacy
- Benefit-risk relies heavily on extrapolation from the reference product's established profile (Correct answer)
- Immunogenicity is not relevant for biosimilars
- Post-marketing surveillance is not required for biosimilars
Correct answer: Benefit-risk relies heavily on extrapolation from the reference product's established profile
Biosimilar benefit-risk assessment uses the reference product's established profile as the foundation, with extrapolation to indications based on demonstrated similarity.
Question 4: A company conducts a Periodic Benefit-Risk Evaluation Report (PBRER). The primary regulatory purpose of this document is to:
- Replace the PSUR for all markets simultaneously
- Present a cumulative reassessment of the product's benefit-risk balance at defined intervals (Correct answer)
- Summarize clinical trial protocols for new indications
- Report manufacturing deviations to health authorities
Correct answer: Present a cumulative reassessment of the product's benefit-risk balance at defined intervals
The PBRER provides a cumulative, interval-based benefit-risk reassessment integrating all new data to determine whether the profile remains favorable.
Question 5: Which type of risk minimization measure goes beyond the standard product label to actively restrict prescribing or dispensing?
- Patient information leaflet
- Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) (Correct answer)
- Dear Healthcare Professional letter
- Black box warning
Correct answer: Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU)
REMS with ETASU impose specific conditions such as certified prescribers, pharmacies, or patient enrollment to ensure safe use beyond standard labeling.
Question 6: In benefit-risk terminology, 'risk tolerance' refers to:
- The maximum dose a patient can receive before toxicity
- The level of risk decision-makers and patients are willing to accept given the expected benefits (Correct answer)
- The statistical power of a safety study
- The threshold for mandatory pharmacovigilance reporting
Correct answer: The level of risk decision-makers and patients are willing to accept given the expected benefits
Risk tolerance reflects the willingness of stakeholdersāregulators, patients, and cliniciansāto accept a given level of risk in exchange for the anticipated benefits.
Question 7: A product's benefit-risk profile is re-evaluated after a new safety signal emerges post-approval. This reassessment should include:
- Only the new safety data
- Updated benefit data, the new risk data, and any changes in the therapeutic context (Correct answer)
- A repeat of all original clinical trials
- Withdrawal of the product pending investigation
Correct answer: Updated benefit data, the new risk data, and any changes in the therapeutic context
A comprehensive reassessment integrates updated benefit evidence, the new risk information, and changes in treatment alternatives or disease context.
PVC Benefit-Risk Assessment 3
Which patient population factor most commonly shifts a benefit-risk balance from unfavorable to favorable for a high-risk drug?